A Clinical Trial to Evaluate the Effect of Grapefruit Juice on the PK/PD of Edoxaban

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-02

Study Completion Date

2025-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to evaluate the effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of edoxaban in healthy adults

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults

NCT04139824

Gout Hyperuricemia

COMPLETED PHASE1

Comparative Bioavailability of Dexketoprofen Trometamol Oral Solution vs Tablet Formulations

NCT02209454

Acute Pain

COMPLETED PHASE1

Phase I Study on Multiple Oral Dosing of CG100649

NCT01154790

Healthy

COMPLETED PHASE1

Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition

NCT00780325

Healthy Volunteers

TERMINATED PHASE1

The Impact of Grapefruit Juice on the Response to Clopidogrel

NCT00817999

Healthy

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pharmacokinetics and pharmacodynamics of edoxaban without coadministration of grapefruit juice will be compared with those after administration of grapefruit juice.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Edoxaban and Grapefruit Juice

* Period 1: Single dose of edoxaban 60 mg administered alone
* Period 2: Single dose of edoxaban 60 mg coadministered with grapefruit juice 3 times daily for 3 days

Group Type EXPERIMENTAL

Edoxaban 60 MG [Lixiana]

Intervention Type DRUG

Single administration of edoxaban

Edoxaban 60 MG [Lixiana] + Grapefruit Juice

Intervention Type OTHER

Coadministration of edoxaban and grapefruit juice

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Edoxaban 60 MG [Lixiana]

Single administration of edoxaban

Intervention Type DRUG

Edoxaban 60 MG [Lixiana] + Grapefruit Juice

Coadministration of edoxaban and grapefruit juice

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults aged 19 to 50 years of age (inclusive) at the time of screening
* Subjects with BMI of 18 to 32 kg/m2 (inclusive)
* Subjects who agree to use medically acceptable methods of contraception and not to donate sperm or oocyte
* Subjects who voluntarily decided to participate in the study and provided written consent to comply with the protocol

Exclusion Criteria

* Subjects with current or history of clinically significant cardiovascular, respiratory, hepatic, renal, hematological, gastrointestinal, endocrine, immunological, dermatological, or neuropsychiatric disease
* Subjects with current or history of clinically significant hypersensitivity reactions or hypersensitivity reactions to the components or constituents of the investigational product
* Subjects who have clinically significant hemorrhage or increased risk of hemorrhage due to the following conditions A. Recent history of gastrointesinal ulcers B. Malignant tumor with a high risk of bleeding C. Recent brain or spinal cord injury D. Recent brain, spinal cord, or opthalmic surgery E. Recent history of intracranial or intracerebral hemorrhage F. Esophageal varices, arterial malformations, vascular aneurysms, or spinal cord or cerebral vascular abnormalities G. Coagulation disorders, thrombocytopenia, or platelet dysfunction H. Recent biopsy or major trauma I. Bacterial endocarditis J. Esophagitis, Gastritis, or Gastroesophageal reflux
* Subjects with a history of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
* Subjects whose eGFR calculated by the CKD-EPI formula is 80mL/min or less at Screening
* Subjects whose AST or ALT levels are more than 2 times the upper limit of normal range, or total bilirubin levels are more than 1.5 times the upper limit of normal range at screening
* Subjects whose coagulation test (aPTT, PT) exceeds the normal range at screening
* Subjects who have taken the following medication or medication known to have significant drug interactions with the investigational product within the 2 weeks prior to the first administration day A. Strong P-gp inhibitor or inducer B. Acetylsalicylic acid, antiplatelet agent, anticoagulant, fibrinolytic agent, non-steroidal anti-inflammatory drug (NSAID), selective serotonin reuptake inhibitor (SSRI), or selective serotonin-norepinephrine reuptake inhibitor (SNRI)
* Subjects who donated whole blood within 60 days or blood components within 30 days, or received blood transfusion within 30 days prior to the first administration day
* Subjects who participated and have been exposed to an investigational product in other clinical study within 180 days prior to the first administration day
* Subjects who consistently consumed alcohol (alcohol 21 units/week \[1 unit = 10 g of pure alcohol\]) within 2 weeks of the first administration day
* Subjects who consumed grapefruit or grapefruit juice within 2 weeks of the first administration day
* Pregnant or breastfeeding women
* Subjects judged unsuitable to participate in the clinical study by investigators due to other reasons, including the results of laboratory tests

Minimum Eligible Age

19 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes